2017 Cancer Advances Report 2: Patient-Centered Treatments, Clinical Trials and New Drugs

In the 21st century, cancer patients receive treatments prolonging life while gaining fuller, higher-quality lives. Research steadily improves survival across cancer types. Physical recovery is our main aim, but %100 health also requires psychological well-being. Cancer only be new treatment approaches increasingly emphasize psychosocial needs.
Technology provides easy access to health information. Patients actively contribute to decisions about illness and treatment. Imaging, precautions and treatment choices consider emotional state and values. The era of unilateral physician decisions is giving way to patient-centered care. Targeted drugs are developed considering lifestyle and environmental factors alongside genetics.
Every patient deserves the best treatment and care. Emerging web-based applications allow daily symptom recording and information access. Navigation applications provide assistance. Preventing chemotherapy nausea is another quality-of-life research focus.
Government Support for Clinical Research
Research is supported by government or private sectors. Important prevention, imaging and treatment-comparison studies attract little private support and mainly rely on government.
Research priorities reflect development and values. They accelerate progress, enable breakthroughs and save lives. Investment across science helps anticipate the future and may eventually prevent cancer and other life-shortening diseases.

Table: Cancer Drugs FDA-Approved Between 1 November 2015-31 October 2016:
|
New Approvals |
For which situations? |
Approval Date |
|
Osimertinib |
Metastatic EGFR T790M-mutated NSCLC progressing during or after EGFR TKI therapy |
November 2015 |
|
Daratumumab |
Multiple myeloma after 3 or more prior treatment lines |
November 2015 |
|
Ixazomib |
Multiple myeloma after at least 1 prior line, combined with Lenalidornidin and dexamethasone |
November 2015 |
|
Necitumumab |
First-line metastatic squamous NSCLC, combined with gemcitabine and cisplatin |
November 2015 |
|
Alectinib |
Progressing metastatic ALK-positive NSCLC / crizotinib intolerance |
December 2015 |
|
Venetoclax |
17p-deleted CLL (chronic lymphocytic leukemia) after one or more treatments |
April 2016 |
|
Cabozantinib |
Advanced kidney cancer after antiangiogenic therapy |
April 2016 |
|
Atezolizumab |
Locally advanced or metastatic urothelial carcinoma after or during platinum chemotherapy—or given with platinum chemotherapy within 12 months of neoadjuvant–adjuvant treatment. |
May 2016 |
Table 2: Among cancer drugs approved from November 2015-31 October 2016, those previously approved for other indications and given new uses
|
New Uses |
For which situations? |
Approval Date |
|
Trametinib and Dabrafenib |
Metastatic melanoma (skin cancer) with BRAFV600E or V600K mutation |
November 2015 |
|
Nivolumab |
Advanced kidney cancer after antiangiogenic therapy |
November 2015 |
|
Ofatumumab |
Recurrent or progressing CLL after partial or complete response to one or two treatments |
January 2016 |
|
Eribulin |
Metastatic liposarcoma after initial anthracycline-containing treatment |
January 2016 |
|
Palbociclib |
Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, with fulvestrant after endocrine therapy |
February 2016 |
|
Obinutuzumab |
Follicular lymphoma, combined with bendamustine |
February 2016 |
|
Everolimus |
Progressing well-differentiated, nonfunctional gastrointestinal or lung neuroendocrine tumors |
February 2016 |
|
Crizotinib |
ROS1-positive metastatic NSCLC |
March 2016 |
|
Lenvatinib |
Advanced kidney cancer after antiangiogenic drugs, combined with everolimus |
May 2016 |
|
Nivolumab |
Recurrent classic Hodgkin lymphoma or progression after autologous hematopoietic stem cell transplantation |
May 2016 |
|
EGFR mutation test v2 |
Detection of EGFR exon 19 deletion or exon 21 substitution mutations to establish erlotinib suitability in NSCLC |
June 2016 |
|
Pembrolizumab |
Recurrent or metastatic squamous head-and-neck cancer after platinum chemotherapy or progression during it |
August 2016 |
|
Atezolizumab |
Metastatic NSCLC progressing after or during platinum chemotherapy |
October 2016 |
Sources
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
J Clin Oncol 35. 2017 by American Society of Clinical Oncology
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.